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ABSTRACT: The association of movement disorders with structural or functional hepatic disease occurs in
three principal scenarios: (1) combined involvement of both organ systems from a single disease entity,
(2) nervous system dysfunction resulting from exposure to toxic compounds in the setting of defective hepatic
clearance, or (3) hepatic and/or neurological injury secondary to exposure to exogenous drugs or toxins. An
important early step in the workup of any patient with combined movement disorders and liver disease is the
exclusion of Wilson’s disease. Diagnostic delay remains common for this treatable disorder, and this has major
implications for patient outcomes. Thereafter, a structured approach integrating variables such as age of onset,
tempo of progression, nature and severity of liver involvement, movement disorder phenomenology, exposure
to drugs/toxins and laboratory/neuroimaging findings is key to ensuring timely diagnosis and disease-specific
therapy. Herein, we provide an overview of disorders which may manifest with a combination of movement
disorders and liver disease, structured under the three headings as detailed above. In each section, the most
common disorders are discussed, along with important clinical pearls, suggested diagnostic workup,
differential diagnoses and where appropriate, treatment considerations.
The association of movement disorders (MD) with hepatic dis-
ease is a noteworthy one. In some instances, it is merely coinci-
dental. In others, it may reflect:
1. Combined involvement of both organ systems from a single
disease entity,
2. Neurological dysfunction secondary to defective hepatic
clearance of toxic compounds, or
3. Hepatic and/or neurological dysfunction secondary to expo-
sure to exogenous drugs or toxins.
A structured approach considering variables such as patient
age, duration and severity of liver disease, MD phenomenology
and ancillary tests can facilitate diagnosis, and oftentimes, institu-
tion of specific treatment. In this review, we provide an educa-
tional and practical overview of MD associated with hepatic
disease. We begin with an overview of liver disease and its diag-
nostic workup, and proceed to discuss the three categories of dis-
orders detailed above. Common conditions are discussed in the
text, while less frequent associations are detailed in Tables S1 and
S2. An approach to diagnosis is suggested in Figure 1. Our
methods are described in supplementary material S3.
A Brief Overview of Liver
Disease
Liver disease is a major cause of premature mortality worldwide. Its
prevalence is increasing, largely driven by alcoholic and non-alcoholic
fatty liver disease, and viral hepatitis. Liver dysfunction is frequently
asymptomatic or produces non-specific complaints such as asthenia or
malaise. Occasionally, more specific abnormalities-jaundice, pruritis,
bleeding diathesis, immunosuppression, oedema-may emerge. Clinical
examination can identify other suggestive features, including palmar
erythema, spider naevi, ascites and hepatomegaly.
Liver dysfunction is most commonly identified through testing a
panel of serum markers, commonly referred to as “liver function
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tests”.1 These comprise markers of hepatocellular dysfunction-alanine
transaminase (ALT) and/or aspartate aminotransferase (AST),
bilirubin—a marker of parenchymal liver dysfunction or biliary
obstruction, and markers of biliary disease such as alkaline
phosphatase(ALP) and gamma—glutamyltransferase (GGT). Further,
other indices eg, albumin and INR, are useful in assessing hepatic syn-
thetic function. However, most are not specific for liver disease. For
instance, AST may increase following muscle injury, elevations in
GGT are common in chronic alcoholics, obese individuals or those
taking enzyme-inducing drugs, and ALP can be deranged in metabolic,
structural or malignant bone disease, and during childhood and preg-
nancy. These tests must therefore always be interpreted in the clinical
context.
Liver injury progresses through a number of stages, beginning
with steatosis (accumulation of fat). This relatively “benign” pro-
cess is often reversible if its primary driver (e.g. alcohol, meta-
bolic syndrome) is addressed.2 Up to half of people with
steatosis develop hepatic inflammation (steatohepatitis)—many
of these will progress to fibrosis/cirrhosis.2 Most cirrhotic
patients exist in a “compensated” state, with decompensations,
marked by the development of ascites, jaundice, encephalopathy
or variceal hemorrhage, occurring in the setting of gastrointesti-
nal bleeding, infection or continued insults eg, alcohol
ingestion.
In addition to defining etiology (Table 1), chronic liver disease
patients should undergo assessments for liver fibrosis, which is a
strong predictor of future morbidity and mortality.3 Blood bio-
markers (often combined with clinical/demographic data) or
imaging techniques (transient elastography) are frequently
employed, though the gold standard remains liver biopsy.
The complexity of liver function testing, detecting hepatic
fibrosis and managing complications mandates the early involve-
ment of a hepatologist in cases of combined MD and hepatic
disease.
Combined Involvement of
the Nervous System and
Liver from a Single Disease
Entity
This category largely comprises genetic disorders which manifest
in childhood or early adolescence. MD phenomenology is var-
ied, but frequently dystonic or ataxic in nature. Liver involve-
ment ranges from mild/asymptomatic, through to fulminant liver
failure. Hepatomegaly is a particular red flag for storage disorders
and other inborn errors of metabolism.
Wilson’s Disease
Wilson’s disease (WD) is the archetypal disorder combining MD
and liver disease. Characterized by the triad of liver disease, neu-
rological abnormalities and psychiatric symptoms, this recessively
inherited condition results from biallelic mutations in ATP7B,
coding for a copper-transporting ATPase. The resulting defective
biliary copper excretion results in systemic copper overload and
end-organ toxicity.4
Most individuals manifest in the 1st–3rd decades of life. Age
and sex are important determinants of disease phenotype, while
ATP7B genotype is an important determinant of penetrance.5,6
Hepatic manifestations often predominate in childhood, while
neurological presentations occur more frequently in adolescence/
early adulthood.4,5
Hepatic manifestations of WD are protean, existing along a
spectrum ranging from completely undetectable through varying
degrees of chronic active hepatitis, progressing if untreated to cir-
rhosis and decompensated liver disease.7 Acute hepatic failure is
the presenting feature in roughly 5% of cases and carries 100%
TABLE 1 Common first-line screening examinations in adults with abnormal liver function tests (LFTs)
Screening test Etiology
Serum copper, caeruloplasmin AND Urinary copper. Slit-lamp examination Wilson’s disease
Hepatitis B surface antigen, hepatitis C antibody Viral hepatitis
Ferritin, transferrin saturation, serum iron, total iron binding capacity Hereditary Haemochromatosis
Tissue transglutaminase IgA Coeliac disease
Alcohol history (+biochemical clues: "MCV, "GGT, AST > 2xALT) Alcoholic liver disease
"BMI, "haemoglobin a1c. Lipid profile. Liver ultrasound or MRI Non-alcoholic steatosis/steatohepatitis
Anti-mitochondrial antibody, anti-smooth muscle antibody, Anti-LKM antibody,
antinuclear antibody, serum immunoglobulins
Autoimmune liver disease
Alpha-1 antitrypsin Alpha-1 antitrypsin deficiency
ALT, alanine transaminase; AST, aspartate aminotransferase; BMI, body mass index; GGT, gamma-glutamyltransferase; LKM, Liver-Kidney microsomal; MCV, mean cell
volume; MRI, magnetic resonance imaging.
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mortality without urgent liver transplant—it is particularly com-
mon in young women.8–11 In such cases of acute hepatic failure,
Coombs-negative intravascular haemolysis (which itself can be a
presenting feature of WD) is an important clinical clue. Acute-
on-chronic liver failure can also occur following sudden discon-
tinuation of therapy.8,9
Neurological manifestations are equally varied, but generally
dominated by MD. Kinnier Wilson asserted in his landmark
paper that tremor was one of the “outstanding features” of WD,
and this has stood the test of time.12 It can be resting, postural
(including the classic “wing-beating”), intention or action tremor
and affects up to 90% of patients with neurological WD at some
time point.13 Though generally first appearing in the upper
limbs, if untreated it may progress to involve the trunk, legs and
head.13 Dystonia is also common, often affecting the facial mus-
culature, producing a “fatuous smile”; again, without treatment,
axial and limb involvement ensues.12–14 Parkinsonism is observed
in roughly 30%, while chorea and ataxia may also be seen. Dys-
arthria, the most common feature of neurological WD, is present
in almost all cases.13,14 Psychiatric disturbances(personality and
behavioral changes, psychosis) and cognitive impairment often
associate with MD.15 MRI abnormalities including basal ganglia,
thalamus and brainstem T2-weighted hyperintensities and in
more advanced cases, the typical “face of the giant panda” or
“face of the panda cub” signs may be apparent.14,16
The approach to diagnosis of WD depends on the clinical
presentation, as the sensitivity and specificity of diagnostic tests
vary in different scenarios. Numerous guidelines have been pub-
lished to aid clinicians in this regard.17,18 In symptomatic individ-
uals, diagnosing WD largely relies on clinical and/or biochemical
identification of systemic copper overload, through demonstra-
tion of elevated urinary copper excretion, reduced serum
caeruloplasmin, ocular Kayser-Fleischer rings or in some cases,
copper overload on liver biopsy.
Clinicians should be mindful of pitfalls in the interpretation of
these screening tests for WD. Kayser-Fleischer rings are present
in only 50% of patients with hepatic WD, but 85%–95% of those
with neuropsychiatric involvement.8 Caeruloplasmin levels may
be reduced in protein-losing nephropathies and enteropathies
and in advanced liver disease of any cause. Cholestatic liver dis-
ease can cause elevated urinary copper excretion, and occasion-
ally, Kayser-Fleischer rings.18 Moreover, in fulminant hepatic
failure due to WD, classic approaches to testing, in particular
serum caeruloplasmin are both insensitive and non-specific.
Additionally, reduced urine output alongside processing delays
limits the utility of urine copper excretion in this setting.10 This
diagnosis therefore requires recognition of other biochemical fea-
tures, classically modest transaminase elevations, low ALP and
ratio of ALP:bilirubin of <2.10,18 In children with hepatic WD,
caeruloplasmin and urinary copper elimination may be mislead-
ingly normal, and liver biopsy may be necessary to establish the
diagnosis.19
Though the ATP7B gene was identified in 1993, genetic het-
erogeneity, incomplete penetrance and the presence of modifier
genes limit the utility of genetic screening as a diagnostic test in
symptomatic WD. Genetic screening alone will miss the
diagnosis in 15%–20% of cases.5,20 Moreover, homozygosity or
compound heterozygosity for pathogenic ATP7B variants does
not imply that disordered copper metabolism, and hence WD,
will ensue.20 Hence, confirmatory biochemical testing is always
required in the presence of positive genetic testing and treatment
decisions should be based on clinical and biochemical rather than
genetic parameters. Genetic testing is useful as a confirmatory
test, and for screening of family members.
Previously a fatal affliction, WD is now treatable through che-
lation therapy(primarily penicillamine and trientine)and/or
reducing intestinal copper absorption using zinc. All therapies
can cause transient neurological deterioration in about 10% of
individuals, recovery from which is often incomplete.21 Other
rare side-effects include hypersensitivity reactions(particularly
with penicillamine), drug-induced cytopenias22 and late develop-
ment of nephrotic syndrome and drug-induced lupus.22
Inborn Errors of Metabolism
Inborn errors of metabolism (IEM) frequently manifest with
complex neurological syndromes associated with liver involve-
ment. Though individually rare, as a whole their cumulative fre-
quency may exceed 1 in 1000, especially in ethic groups where
consanguineous marriage is commonplace.23 Clinical features are
highly heterogeneous, depending largely on residual enzyme/
metabolic pathway function. This, combined with the sheer
number of individual disorders (>1000) makes detailing specifics
about individual conditions of limited utility in clinical prac-
tice.24 Saudubray et al. in 2019 proposed a simplified IEM classi-
fication system, grouping disorders according to the size of the
affected molecule(“small” or “complex”), the nature of the defect
(“accumulation” and “deficiency”) and the effects on energy pro-
duction.25 This “clinically friendly” approach forms the basis of
our discussion of IEMs. We also highlight red-flags which should
arouse suspicion, and detail an approach to testing (see Tables 2
and 3).
Small Molecule “Accumulation” Disorders
This group includes the organic acidemias, urea cycle
disorders and amino acid catabolism defects.31,32 Most do not
interfere with pre-natal development, and present after a period
(from hours to years) of apparent post-natal normality, classically
with acute, intermittent or progressive encephalopathy some-
times triggered by stressors such as dehydration, protein load, sur-
gery, infection, fasting, or certain drugs.25 Features may include
hypotonia, tremor, respiratory distress, vomiting, lethargy and
dehydration, progressing if untreated to seizures, coma and death.
Sepsis is often suspected, and a history of death of siblings, poten-
tially mis-attributed to infection, heart failure or intra-ventricular
hemorrhage may be present.31 Many of these disorders are
treatable.
Partial enzyme deficiencies giving variant presentations in late
childhood and adulthood are increasingly described, often man-
ifesting with progressive motoric, psychiatric and behavioral
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syndromes (sometimes mis-diagnosed as cerebral palsy).30 The
most common MD observed are ataxia and dystonia.
Within this group, glutaric aciduria type 1 is most commonly
associated with MD, but liver involvement is rarely prominent.
Another noteworthy condition is ornithine transcarbamylase
deficiency (OTCD), the most common urea cycle disorder. This
X-linked disorder usually presents in childhood, but adult pre-
sentations are increasingly recognized (eg, in males with partial
deficiencies, or heterozygous females) and are an important
differential diagnosis of adult hyperammonemic encephalopathy.
Acute(sometimes recurrent) liver failure, is well recognized in
OTCD, as are more minor degrees of liver dysfunction.33 Early
measurement of serum ammonia, amino acid profile and urinary
orotic and organic acids helps to seal the diagnosis.
Complex Molecule “Accumulation”
Disorders
This group comprises probably the best recognized/defined
IEMs, the lysosomal storage disorders (LSD), as well as rarer large
molecule metabolism disorder eg, glycogenosis and neural lipid
storage disorders.25,34 As with their small molecule counterparts,
they are generally devoid of antenatal manifestations but can pre-
sent with progressive neurodegeneration during childhood or
adult life, alongside variable “storage signs” eg, hepatomegaly,
and other disease specific multi-organ involvement. As with
small molecule “accumulation” defects, some are (at least par-
tially) treatable. An overview of some of these disorders is pro-
vided below:
TABLE 3 Red flags for possible inborn errors of metabolism (note:




Autosomal recessive inheritance pattern
Encephalopathic crises+/ triggers (infection, surgery,
medications eg, valproate)
Neonatal death of a sibling
Protein aversion/preferred vegetarianism in patient or
family members
Unexplained post-partum neurological symptoms (urea
cycle disorder)30
Episodic neurological symptoms











TABLE 2 Suggested screening for inborn errors of metabolism (IEM)
according to clinical suspicion
The clinical similarities between many IEM makes it
appropriate to cast a wide net as part of initial screening*.26
The first step should involve a review of newborn dried
blood spot results (screened disorders vary among health
systems). Thereafter, appropriate tests, depending on
clinical suspicion, may include:
Suspected small molecule “intoxication” disorder
Serum ammonia level (may be normal outside of crises,
especially in partial deficiency).
Urine organic acid analysis (detection of organic acidemias
and some fatty acid oxidation defects)
Plasma and urine amino acids
Serum lactate
Suspected small molecule “energy deficit” disorder
Serum ketones and glucose (often both low during acute
FAOD presentations)
Serum free fatty acids (FAOD)
Plasma acylcarnitine profile and serum free and total
carnitines (low in disorders of carnitine transport)
Serum lactate:pyruvate ratio taken 1 hour after feeding
(mitochondrial respiratory chain defects)27
Cerebrospinal fluid lactate, pyruvate, amino acids and
protein27
Serum thymidine (especially in MNGIE)27
mtDNA genetic testing
Tissue analysis may be necessary to seal the diagnosis27
Suspected disorder of “complex molecule” metabolism
Lysosomal enzyme testing (most lysosomal storage
disorders)
Plasma oxysterols (Niemann Pick type C)
Serum very long chain fatty acid, pristanic acid and
phytanic acid analyses (peroxisomal disorders)
*Many of these tests are optimally performed after an overnight fast.26 Testing
should be interpreted by a metabolic specialist, as it is oftentimes the pattern of
abnormality, rather than the absolute individual values, which suggest the
diagnosis.28
IEM, Inborn errors of metabolism; FAOD, fatty acid oxidation defects;
MNGIE, mitochondrial neurogastrointestinal encephalopathy; mtDNA, mito-
chondrial DNA.
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Gaucher disease(GD), the most common LSD, is caused by
recessively inherited mutations in the GBA1 gene encoding the
lysosomal enzyme, glucocerebrosidase. It results in accumulation
of substrate-laden macrophages (Gaucher cells) in the liver,
spleen, bone marrow and other organs, producing the character-
istic multi-system manifestations.35
Systemic features, common to all sub-types, comprise
hepatosplenomegaly, bone involvement (stunted growth, painful
bone crises) and cytopenias (most commonly thrombocytope-
nia).35 Liver enlargement is usually detected incidentally on
physical examination or imaging, but only rarely associated with
significant hepatic injury or fibrosis. Focal lesions-usually benign
Gaucheromas- are common, but GD patients have an increased
risk of hepatocellular carcinoma, therefore this important differ-
ential diagnosis must always be kept in mind.35,36
Type 1 GD, the most prevalent subtype, is usually diagnosed
between 10 and 20 years of age, but may remain asymptomatic
throughout life. It was previously considered free of neurological
symptoms,35 but is now recognized to confer significantly
increased risk of Parkinson’s disease (often with more severe cog-
nitive and non-motor disease progression).37 Types 2 and 3 are
earlier in onset. They may manifest pre-natally as foetal hydrops,
arthrogryposis and dermatologic abnormalities, or post-natally as
failure to thrive alongside neurological features such as bulbar
dysfunction, spasticity and horizontal oculomotor abnormalities.
Movement disorders, including progressive myoclonus epilepsy,
ataxia and dystonia (dystonic opisthotonus, cervico-facial dysto-
nia or paroxysmal dystonic events) are frequently
encountered.38,39
Diagnosis is established by demonstrating deficient
glucocerebrosidase activity in leukocytes or cultured fibroblast,
and genetic analysis. Treatment is effective for the systemic, but
not for neurological manifestations.40
Niemann-Pick disease type C (NPC) is a progressive neuro-visceral
disorder caused by bi-allelic mutations in either the NPC1 (95% of
cases) or NPC2 genes, resulting in lysosomal accumulation of
unesterified cholesterol and other lipids. It manifests along a spec-
trum ranging from a severe, rapidly progressive neonatal illness to
slowly progressive late-onset neurodegeneration.41
Early life presentations are often dominated by systemic
manifestations-liver disease with cholestatic jaundice, hepatospleno-
megaly and occasionally, acute liver failure.42
In adolescent/adult-onset cases, neuropsychiatric features are
usually prominent.43 The combination of progressive ataxia, cog-
nitive decline, vertical supra-nuclear gaze palsy and psychiatric
features is particularly suggestive.44 Dystonia (particularly affect-
ing the limbs and/or face), seizures, deafness and gelastic cata-
plexy are other important features.44 Myoclonus, parkinsonism
and chorea are also described.42,45 All patients with NPC even-
tually become demented.46 Visceral manifestations may be subtle,
and hepatomegaly may go unrecognized if not specifically
sought.
Analysis of plasma oxysterols is the first step in diagnostic eval-
uation. Detection of pathogenic mutations in NPC1 and NPC2
genes confirms the diagnosis. Filipin staining of cultured fibro-
blasts is no longer recommended for initial screening.42
Neuropsychiatric manifestations progress with variable speed.
Conversely, hepatic manifestations tend to remain stable or
regress.45,47 Miglustat may slow disease progression.42,43
GM1 gangliosidosis, a rare disorder of reduced beta-
galactosidase activity, primarily manifests in infancy (type 1) or
childhood (type 2) with coarse facial features, dysostosis,
hepatosplenomegaly, ataxia, seizures, macular “cherry red” spot
and progressive neurocognitive decline. Milder adult onset pre-
sentations (type 3) may be diagnostically challenging due to the
absence of “typical” skeletal and neurovisceral findings.48,49 Gen-
eralized dystonia with prominent perioral/facial involvement is
almost universal, and may be accompanied by parkinsonism.49,50
MRI brain is generally abnormal, showing bilateral putaminal
T2-weighted hyperintensities.49,50 Diagnosis is established
through beta-galactosidase enzyme analysis or genetic testing of
the GLB1 gene.
The majority of mucopoysaccharidoses(MPS) have neurological
involvement as a core feature.34 Dystonia, typically generalized
with prominent facial/oromandibular involvement (sometimes
producing characteristic “grimacing”) is the most typical MD,
though ataxia and parkinsonism can also be seen.50 Hepatomeg-
aly is a core disease feature, though despite its large size, hepatic
dysfunction is not universal.51 Clinical pointers to MPS include
coarse facial features, skeletal deformities, recurrent infections
and hernias.
Small and Complex Molecule “Deficiency”
Disorders
These disorders, which impair metabolism of critical small (eg,
amino acids, fatty acids, metals) or large (eg, peroxisomal
disorders) molecules distal to the defective metabolic process
frequently impair neurodevelopment and often present at birth.
Severe multi-system anomalies with complex neurological phe-
notypes are frequent.
Peroxisomal disorders generally encompass varying degrees of
liver dysfunction, neurological decline, retinopathy, renal
involvement and sensorineural hearing loss.52 Foetal
dysmorphism (particularly craniofacial) is common.31,52
Neurological involvement range from infantile onset, rapidly
progressive and lethal phenotypes through to late-onset disease
or even isolated hearing or visual problems.52 Brain imaging
characteristically shows white matter signal abnormality, accom-
panied in severe cases by malformations of cortical development,
callosal dysgenesis and brain atrophy. Cerebellar ataxia and
dystonia are commonly observed MD, though tremor may be
prominent in patients with alpha-methylacyl-CoA racemase
(AMACR) deficiency.52
The nature and severity of liver involvement varies among
individual disorders, but often comprises hepatomegaly alongside
steatosis and/or steatohepatitis, occasionally progressing to liver
failure.53 Elevated serum very long chain fatty acids(VLCFA)
suggest the diagnosis, which is confirmed through genetic
testing.
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Coeliac Disease
Coeliac disease (CD) is a multi-system autoimmune disorder
driven by dietary gluten ingestion in genetically susceptible indi-
viduals.54 It affects roughly 1% of the population, typically man-
ifesting with symptomatic enteropathy. Extra-intestinal
manifestations-dermatitis herpetiformis, arthritis, liver involve-
ment and neurologic manifestations-are also common.54
The cerebellum is particularly vulnerable to CD-related
injury,55 and MD in CD largely stem from cerebellar dysfunc-
tion.56 Gait ataxia is most common, though numerous “ataxia-
plus” syndromes, often comprising cortical myoclonus either as
tremor or progressive myoclonic ataxia, have been described.57–59
Loss of cerebellar inhibition of cortical sensorimotor excitability is
the likely driver of myoclonus.60 Another peculiar phenotype is
stimulus sensitive/action-induced foot myoclonus, which has fre-
quently been associated with CD.61 These “cerebellar-driven” phe-
notypes respond poorly, if at all, to gluten-free diet or
immunotherapy.
Chorea is the other major CD-related MD. Almost all cases
have been women presenting with sub-acute generalized chorea
in later life, though florid presentations and onset in young age
are reported.62,63 CD-related chorea tends to respond well to
gluten-free diet.62,63
Liver involvement occurs in up to 40% of adults and 60% of
children with CD,64 and patients have 6 to 8-fold greater risk
of chronic liver disease as compared to the general population.
Manifestations range from asymptomatic transaminitis (the most
common presentation) to rapidly progressive liver failure.64
Most individuals with coeliac hepatitis show no outward signs of
liver derangement, the disorder being picked up only through
routine liver function testing.64
Biochemical and histologic markers of liver injury should
improve within 6–12 months of institution of a gluten-free
diet—this confirms the diagnosis. Lack of improvement suggests
co-existence of another pathology (particularly autoimmune
hepatobiliary disease and/or autoimmune hepatitis), established
liver injury and fibrosis or a disease complication eg,
lymphoma.64
Features which should make clinicians consider a diagnosis
other than coeliac hepatitis include64:
1. Transaminase elevation >5xULN




Aceruloplasminemia is a late-onset autosomal recessive disorder
combining systemic and brain iron overload, caused by mutations
in the ceruloplasmin (CP) gene.65 Most cases have been reported
from Japan.
Neurological symptom onset is generally between 40–60 years
of age, though systemic features including diabetes mellitus and
microcytic anemia are usually present for years beforehand.65
Symptoms include progressive cerebellar dysfunction, cognitive
decline and choreodystonic movements of the cranio-facial
region.65–67 Caucasian patients more frequently develop parkin-
sonism compared to their Japanese counterparts, and are more
likely to exhibit cognitive and/or psychiatric symptoms at disease
outset.65–67 Retinopathy is common in Japanese patients, but is
rarely symptomatic.66
Hepatic iron overload is almost universal, though symptomatic
liver dysfunction and progression to cirrhosis are rarely
reported.66,68 Some cases show mild to moderate fibrosis on liver
biopsy.69
Biochemical pointers to the diagnosis include reduced serum
ceruloplasmin alongside elevated serum ferritin. Brain MRI usu-
ally demonstrates iron deposition in the basal ganglia, thalami
and dentate nuclei. Definitive diagnosis requires identification of
bi-allelic pathogenic CP variants. Iron chelation is effective in
reducing systemic iron overload, but its effectiveness for neuro-
logical disease remains dubious, and its administration not with-
out potential side-effects eg, cytopenias66; phlebotomy and fresh
frozen plasma are also sometimes employed.
Symptomatic aceruloplasminemia has also recently been
described among heterozygous CP mutation carriers. In these
patients, neurological symptoms (particularly MD) predominate,
systemic manifestations are rare, serum ferritin levels often nor-
mal and ceruloplasmin levels generally mildly below the lower
limit of normal.70
Ataxia Telangiectasia
Ataxia telangiectasia (AT) is a phenotypically diverse, multisystem
autosomal recessive disorder characterized by progressive neu-
rodegeneration, immunodeficiency and predisposition to
malignancy.
The clinical features extend far beyond its double-barreled
eponym, and are influenced largely by residual ATM kinase
activity rather than genotype.71 Most affected children manifest
in a “classic” fashion, with progressive gait imbalance, falls and
clumsiness first becoming evident around 12–18 months of age.
They often have a severe disease course with progressive gait
imbalance, loss of ambulation and eventual wheelchair depen-
dency. Their childhood is often marred by recurrent sino-
pulmonary infections, stunted growth, and appearance of other
MDs including dystonia, chorea, tremor and myoclonus.71 Most
succumb to infection or malignancy within the first 3 decades of
life.72
Up to 1/3 of affected individuals present later in life with
milder “variant” AT. The dominant MD in such cases is often
not ataxia, but rather dystonia (especially cervical, axial or
myoclonus-dystonia phenotypes) or chorea.71,72 Most of these
individuals develop ataxia over time, culminating in complex
MD phenotypes.71
Liver disease develops in most patients with AT.73 Prevalence
of steatosis and fibrosis correlate with disease duration, and most
adults will exhibit abnormalities of liver function testing.73,74
Due to the heightened risk for malignancy, hepatocellular carci-
noma should also be considered in those with abnormal liver
function, or hepatic imaging.
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Clinical (cutaneous and conjunctival telangiectasias, oculomo-
tor apraxia) and biochemical (elevated alpha-fetoprotein) features
may suggest the diagnosis,71 which is confirmed by genetic anal-
ysis of the ATM gene.
Neuroacanthocytosis
Neuroacanthocytic disorders are characterized by progressive
neurodegeneration in association with morphologically abnormal
erythrocytes bearing thorn-shaped surface projections
(acanthocytes).75 The two principal disorders are autosomal
recessive chorea acanthocytosis(caused by VPS13A gene muta-
tions) and X-linked McLeod syndrome(due to XK gene
mutations, resulting in absence of the Kx blood group antigen).
Chorea acanthocytosis generally manifests in the 3rd–4th
decade of life, whereas McLeod syndrome begins later(4th–5th
decade). In both, MD are prominent, taking the form of
generalized chorea, ataxia and marked perioral choreodystonic
movements (particularly in chorea-acanthocytosis) often produc-
ing early and prominent feeding problems. Stereotyped sudden
lapses in axial and leg tone producing both head drops and a
peculiar “rubber man” gait, may become evident later in the dis-
ease course.76 Secondary tics, parkinsonism, seizures, cognitive
and neuropsychiatric abnormalities may also be evident.75 Axonal
peripheral neuropathy and myopathy producing distal
amyotrophy is common. The majority of patients with McLeod
syndrome develop a cardiomyopathy.75 Serum CK (a cheap and
simple test) is generally high, and LDH and liver enzymes often
elevated. Hepatomegaly is seen especially in McLeod syndrome,
but progression to cirrhosis or liver failure is not described.75,77
Acanthocytes are often evident on blood film, though identifica-
tion may require repeated testing. Some cases never exhibit
acanthocytes, hence molecular genetic analysis is the preferred
method of diagnosis. MRI brain generally shows striking caudate
atrophy. Kell antigen testing is useful if considering McLeod
syndrome.
Importantly, acanthocytes, or erythrocytes with similar mor-
phological features (echniocytes, spur cells) can occur secondary






One of the central roles played by the liver is that of detoxifica-
tion, both of endogenous by-products of metabolism and of
exogenous substances. When these systems fail, neurotoxic com-
pounds, such as ammonia, may accumulate in the bloodstream,
cross the blood–brain-barrier and producing neurological distur-
bances. This section largely encompasses two syndromes, one
acute (hepatic encephalopathy) and one subacute/chronic
(acquired hepatocerebral degeneration), which can be differenti-




Acquired hepatocerebral degeneration (AHD) is a poly-
symptomatic neurobehavioral syndrome occurring in the setting
of advanced liver disease.78 Its prevalence depends on the popu-
lation studied, ranging from about 2% of unselected cirrhotic
patient to >20% of people with end-stage liver disease.79 AHD
can result from any liver affectation,80,81 though a critical factor
appears to be the development of porto-systemic shunting.80
Most affected patients are between 40 and 70 years of age,79–81
but children are not immune.82
The most common phenotype of AHD is that of atypical par-
kinsonism, which in contrast to idiopathic Parkinson’s disease
(PD), is bilateral, symmetrical, and accompanied by
postural(rather than rest) tremor and early ataxic gait impairment
and falls.80 Other phenotypes are described, including an “ataxia-
plus” disorder (with coexisting dystonia, seizures or tremor) and
a neuropsychiatric syndrome.81 Onset is generally sub-acute over
several weeks to months, often coincident with worsening of
liver disease and reaches maximal severity after an average
of 7 months.80 Cognitive involvement is common, and patients
are frequently apathetic and bradyphrenic, though language and
praxis is generally preserved.79–81 Response to levodopa is
variable.81
Other MD may be apparent. Up to half exhibit focal dystonia,
most commonly involving the face (blepharospasm and/or
oromandibular dystonia),80 which may resemble tardive
orobuccolingual movements.79,83 Dysarthria and dysphagia are
frequent. Leg tremor is distinctly unusual.80
All patients exhibit bilateral pallidal T1-hyperintensities on
MRI, reflecting pallidal manganese deposition which is critical to
AHD pathogenesis.80,81,84 These changes are identical to those
observed in other forms of manganism, including from occupa-
tional exposure, total parenteral nutrition and illicit drug use.80,85
Radiologic findings alone cannot be relied upon to make the
diagnosis, as these are present in 75%–100% of cirrhotic individ-
uals, regardless of the presence of neurological symptoms.86,87
Serum manganese levels are always elevated, though the degree
of elevation does not correlate with neuroimaging abnormali-
ties.80,85 Liver transplantation often leads to normalization of
serum manganese levels and brain MRI changes, but the effects
on the clinical syndrome may be minimal.81 If recovery ensues,
it is generally slow, though lazaroid improvements within hours
of surgery have been reported.79,83,88
Hepatic Encephalopathy
Along with coagulopathy and jaundice, hepatic
encephalopathy(HE) is a cardinal indicator of critical failure of
hepatic synthetic and detoxifying functions. It heralds a
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significant change in disease course-severe hepatic encephalopa-
thy carries a 50% mortality at 1 year.89
HE comprises two principal components: a) a disorder of vigi-
lance and arousal, and b) neuromuscular excitability. Conscious
alterations exist along a spectrum. Early symptoms include poor
attention, sleep–wake cycle disturbances and anxiety. If
unchecked, these progress to personality change, dis-inhibition,
apathy, disorientation, memory impairment and eventually coma
and obtundation.90,91
Negative myoclonus is the other hallmark feature of HE,
often manifesting as the flapping tremor of asterixis. This is easily
appreciated in the upper limbs, though is often apparent in other
regions if tested.92 Importantly, asterixis is not pathognomonic of
liver dysfunction, and can be observed in other, often metabolic,
derangements.
From a pathomechanistic and management perspective, HE
should be considered according to the acuity of its development.
Most HE is of the “chronic” type, occurring as it were in
patients with longstanding cirrhosis who experience a slow pro-
gressive decline in liver function, leading to portosystemic
shunting of toxic substances, which at some point reaches a criti-
cal threshold such that neurological impairment becomes mani-
fest. HE in this population is frequently triggered by extraneous
factors eg, sepsis, electrolyte disturbance, constipation or intesti-
nal hemorrhage. In contrast, HE occurring in patients with acute
or fulminant liver failure, defined as rapid (<26 weeks) develop-
ment of encephalopathy and hepatic synthetic dysfunction
(INR≥1.5) in a patient without pre-existing cirrhosis or chronic
liver disease, is more problematic. Rapid osmotic shifts can pro-
duce significant cerebral oedema, increased intracranial pressure
and the threat of brain herniation.93
In “chronic” HE, serum ammonia levels are often elevated,
but there is little correlation with the presence and/or severity of
the neurocognitive syndrome.94 In contrast, ammonia levels do
predict outcomes in acute hepatic failure, where venous ammo-
nia in excess of 150 μmol/L is an independent predictors of
increased intracranial pressure, cerebral herniation and death.94,95
Treatment of HE aims to reduce systemic ammonia load.
Intestinal ammonia production is reduced through administration
of non-absorbable disaccharides, sometimes supplemented by oral
antimicrobials.93,96 This should occur concurrently with revers-
ing any triggers of hepatic decompensation eg, infection, gastro-
intestinal bleeding or drug/toxin administration, and
consideration of liver transplantation. In those with “acute” HE,
clinical and neuroradiologic signs of increased intracranial pres-
sure should be carefully sought, and the patient aggressively man-
aged in a neurocritical care environment.93
HE and AHD are commonly conflated in the literature, but
they are distinct entities with different pathomechanisms,
responses to treatment and clinical courses. Differentiating
between them is rarely cumbersome, though both may coexist at
certain points in time. The following pointers are useful to keep
in mind:
• Altered level of consciousness, a core feature of HE, is absent
in AHD.
• AHD generally assumes an akinetic-rigid phenotype, whereas
abnormal movements in HE are usually hyperkinetic(particularly
myoclonic).
• Clinical deficits of HE often respond to ammonia-lowering





Combined hepatic and neurological syndromes secondary to
intake of exogenous substances, either recreationally or as pre-
scription medication, ranks among the most common causes of
MD and hepatic disease. Below is a summary of the most com-
mon scenarios to consider:
Alcohol-Related Disease
Alcohol produces nefarious effects principally on the central nervous sys-
tem and liver, and tops the list of toxic substances combining MD and
liver disease. Movement disorders are a common symptom of alcohol-
related CNS disease, and primarily exhibit one of two phenotypes:
Ataxia
Ataxia is the principal MD encountered following alcohol inges-
tion, and can occur in any number of clinical scenarios:
1.Acute Intoxication
The features of acute alcohol intoxication are highly variable.
They depend on the quantity ingested, the period of time over
which ingestion occurred, body habitus, tolerance and co-
ingestion of other toxic substances.97 Neurologic symptoms fol-
low a dose-dependent pattern, beginning with increased talka-
tiveness and relaxation, followed by slurred speech, impaired
judgment, lack of coordination and ataxia.97 Examination during
moderate intoxication often reveals gait ataxia as well as saccadic
ocular pursuits and other cerebellar eye signs.98
2.Cerebellar degeneration
Alcoholic cerebellar degeneration is the most common acquired
toxic ataxia, affecting up to 50% of long-term alcohol abusers.99
The syndrome is one of pronounced gait and stance ataxia with rel-
ative absence of upper limb, speech or oculomotor deficits. The
ataxia often begins subacutely after many years of chronic alcohol-
ism and is frequently progressive. Brain imaging typically shows cer-
ebellar atrophy with preferential involvement of the vermis.100
Early theories favored nutritional deficiencies and/or direct cellular
toxicity as an aetiopathologic explanation, though recent evidence
suggests immune mechanisms may be at play.100
1. Nutritional syndromes
Multifactorial deficiencies in B-vitamins, particularly thiamine,
are common in chronic alcoholics, and can impair diencephalic,
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brainstem and cerebellar functions.101 Wernicke’s encephalopa-
thy (WE) is a largely reversible syndrome manifesting with vary-
ing degrees of confusion, ataxia and ophthalmoplegia.98 If
unchecked, Korsakoff syndrome may ensue, the most striking
feature of which is marked, especially anterograde amnesia.98,101
Tremor
Tremor occurs both in the setting of chronic alcoholism, and of
alcohol withdrawal. Over half of chronic alcoholics experience
tremor, most commonly large-amplitude postural hand
tremor.102 This is rarely disabling, and its severity decreases with
continued abstinence.92 Other tremors have been described in
chronic alcoholics, including position-dependent upper-limb rest
tremor resembling parkinsonian tremor, and 3 Hz leg
rest tremor, which is best appreciated either in the standing posi-
tion with the knees bent, causing a bobbing motion, or when
lying supine with hips and knees flexed to 90 degrees, as a
kicking movement.92 Tremor also emerges following intentional
or unintentional abrupt cessation of chronic, heavy drinking,
alongside other symptoms of alcohol withdrawal such as halluci-
nations (visual, tactile, auditory), autonomic activation and
seizures.103
Other MD occurring in the setting of alcohol withdrawal
include transient parkinsonism, myoclonus, dystonia and a variety
of choreiform movements.104–107
The manifestations of alcoholic liver disease are vast. Most
problem drinkers will develop alcoholic steatosis, which is gener-
ally reversible upon stopping alcohol consumption.108,109 With
continued drinking, progression to steatohepatitis and eventually
fibrosis and cirrhosis occurs. However, only 10%–20% of people
with alcoholic steatosis who continue to drink will progress to
fibrosis, indicating a significant role for other modifiers in deter-
mining disease expression-these include age, sex, race, comorbid
conditions such as diabetes and obesity, and genetics.108,110
Importantly, a number of MD, particularly essential tremor
and myoclonus-dystonia may be alcohol-responsive, resulting in
over-indulgence in order to mitigate disability.
Thiamine supplementation should be given for all cases of
suspected or confirmed alcohol-related neurological disease.
Illicit Drug Use
The association of MD alongside hepatic disease should always
lead to consideration of illicit drug use. At-risk behaviors in drug
abusers place them at heightened risk for liver disease, not only
because of co-infection with hepatitis viruses, but also because of
a propensity for heavy alcohol consumption. Prevalence of hepa-
titis C in intravenous drug users is up to 90%,111 and over 50%
meet criteria for harmful/hazardous drinking.112 Up to 25% of
injection drug users will have cirrhosis.113,114
Drug-induced MD either result from the pharmacologic
properties of the ingested substance or from adulterants.115 Com-
mon toxindromes are detailed below:
Cocaine blocks the pre-synaptic re-uptake of dopamine and
other catecholamines, with euphoric and motoric consequences.
Transient orobuccal and limb chorea, known as “crack dancing”,
is a dramatic phenotypic manifestation which can persist for sev-
eral days.115 Motor and verbal tics are also common. Chronic
abuse can lead to down-regulation of dopaminergic transmission,
producing parkinsonism during periods of abstinence.116 Interest-
ingly, prior neuroleptic use may be a risk factor for the develop-
ment of cocaine-related MD; conversely, cocaine may
precipitate acute dystonic reactions in neuroleptic users.115,117,118
Amphetamine and methamphetamine act similarly to cocaine,
producing euphoria, sympathetic arousal, chorea, tremor, ataxia
and seizures.115,119 Delusions of formication are a common neu-
ropsychiatric feature of chronic use, as is punding.119
Ephedrone, synthesized from pseudoephedrine using potassium
permanganate as an oxidant, is predominantly encountered in
former Soviet states. Some users have developed striking
subacute-onset akinetic-rigid parkinsonism due to secondary
manganism-the likely culprit being the oxidizing agent.115,120
Medications Commonly
Administered for Liver Diseases
Treatment of liver diseases varies according to etiology, severity
and patient comorbidities. Numerous medications may be
employed and these should always be considered as potentially
causative of observed MD.
Two particularly important examples are given below:
TABLE 4 Examples of prescribed medications which may cause derangements in liver function testing (along with usual pattern of liver injury)

























HAART, highly active anti-retroviral therapy; NSAIDs, non-steroidal anti-inflammatory medications.
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Calcineurin Inhibitors
Liver transplant is the treatment of choice for chronic
decompensated liver failure and fulminant hepatic failure of any
etiology. Improvements in immunosuppressive regimes in recent
decades have significantly improved patient and graft survival.121
This however comes with complications such as malignancies,
opportunistic infections and organ toxicities.121 Neurotoxicity is
particularly encountered with the calcineurin inhibitors(CNI),
ciclosporin and tacrolimus.
Neurotoxicity affects most CNI-treated patients. Mild mani-
festations such as tremor affect up to 80% of CNI (especially
tacrolimus)-treated patients. This is generally a symmetrical rest
and action tremor of the upper limbs, though facial and lower
limb muscles may be involved.122 Other rarer manifestations
include parkinsonism, opisthotonus and severe rigidity.123 Severe
toxicity may progress to stupor and coma.124 Neurological effects
are not strictly dose-dependent, and can occur with normal drug
trough levels. MRI brain may demonstrate features supportive of
CNI-neurotoxicity such as PRES or cortical hyperintensity, par-
ticularly in the cingulate or occipital regions.125 Management
involves dose reduction, and therefore requires close cooperation
with the transplant team.
Metronidazole
Metronidazole is occasionally in the management of hepatic enceph-
alopathy, or for treatment of intercurrent infections in patients with
liver disease.126 Patients receiving metronidazole may develop a syn-
drome characterized by ataxia, cerebellar dysarthria, neuropathy and
occasionally, encephalopathy.127,128 Toxicity can result either from
high-dose or cumulative low dose exposure. Importantly, hepatic
dysfunction may predispose to this unusual complication.128 MRI
brain classically shows prominent, reversible, T2-weighted and




The principal drugs with hepatotoxic potential prescribed in MD
practice are valproate and tolcapone.129 Valproate is employed in
a variety of clinical scenarios for mood stabilization, seizure con-
trol and relief of myoclonus. It can produce a number of hepatic
syndromes, including:
- Symptomatic isolated hyperammonemia with minimal or no
evidence of liver dysfunction, usually manifesting within weeks
of treatment initiation or dose escalation with progressive
obtundation and confusion, which is reversible upon stopping
treatment.130
- Acute hepatocellular injury, with significant transaminitis,
hyperbilirubinemia and hepatic synthetic dysfunction occasion-
ally progressing to liver failure.
- Reye-like syndrome in children receiving valproate follow-
ing viral infection.
Tolcapone is a catechol-O-methyltransferase inhibitor used as
an adjunctive therapy in the management of PD. In up to 5% of
patients, it results in significant transaminase elevation. Though
usually self-limiting, some people have experienced progressive,
sometimes lethal hepatocellular injury.131
Intake of medications for other ailments (Table 4) as well as
herbal and/or traditional medications should also be considered,
as they can have significant hepatotoxic potential.
Conclusion
The myriad of clinically and pathophysiologically distinct condi-
tions combining MD and liver disease can, at first, seem bewil-
dering. Many of the disorders discussed herein (particularly
inherited causes) are vanishingly rare, their systemic manifesta-
tions non-specific and their MD phenotypes incompletely char-
acterized.29 Moreover, partial enzyme deficiencies producing
variant presentations in adulthood are increasingly being recog-
nized. One must also remember that combined MD and liver
symptomatology can be the product of simple happenstance, due
for example to two independent organ pathologies, diffuse meta-
static or inflammatory disease.
Nevertheless, a systematic approach considering age of onset,
MD phenomenology, developmental and family history and
other neurological/systemic features can effectively guide diag-
nostic testing (Fig. 1). For example, early age at onset, complex
neurological phenotypes and other “red flags” suggest inherited
IEMs; conversely, stigmata of chronic liver disease or a history of
alcohol or substance misuse may rather suggest acquired disorders
stemming from critical failure of hepatic detoxifying functions.
Wilson’s disease should always be excluded. Disentangling the
syndrome may require exhaustive testing and multidisciplinary
collaborations, but given the treatable nature of many of these
conditions, is certainly worthwhile.
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